The two firms have a joint research and licensing agreement for development of topical treatments for various viral diseases combining Exovir's patented surface-active gel with two recombinant cytokines. Agreement grants Genentech the right to use combinations of the substances for research and commercial purposes and provides for Exovir to receive royalties based on a percentage of the net revenues from commercial sale of products developed.
You may also be interested in...
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Lumoxiti, AstraZeneca's drug for hairy cell leukemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
Tyto Care will use the proceeds to expand its telehealth and remote monitoring solution to the US, Europe, and Asia, and add AI capabilities.